No connection

Search Results

SRZN vs YDES

SRZN
Surrozen, Inc.
BEARISH
Price
$31.56
Market Cap
$371.2M
Sector
Healthcare
AI Confidence
95%
YDES
YD Bio Ltd
BEARISH
Price
$5.25
Market Cap
$369.9M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
SRZN
--
YDES
--
Forward P/E
SRZN
-8.85
YDES
--
P/B Ratio
SRZN
-1.64
YDES
1.15
P/S Ratio
SRZN
106.77
YDES
724.75
EV/EBITDA
SRZN
-6.74
YDES
-3.28

Profitability

Gross Margin
SRZN
0.0%
YDES
30.44%
Operating Margin
SRZN
-2393.75%
YDES
-444.59%
Profit Margin
SRZN
0.0%
YDES
-276.58%
ROE
SRZN
--
YDES
-42.69%
ROA
SRZN
-35.75%
YDES
-25.43%

Growth

Revenue Growth
SRZN
-19.4%
YDES
95.6%
Earnings Growth
SRZN
--
YDES
--

Financial Health

Debt/Equity
SRZN
--
YDES
0.0
Current Ratio
SRZN
9.22
YDES
13.18
Quick Ratio
SRZN
9.01
YDES
12.91

Dividends

Dividend Yield
SRZN
--
YDES
--
Payout Ratio
SRZN
0.0%
YDES
0.0%

AI Verdict

SRZN BEARISH

SRZN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is operating with negative equity (Price/Book: -1.64) and an unsustainable Price/Sales ratio of 106.77, suggesting the current valuation is entirely speculative. While the current ratio of 9.22 provides a temporary liquidity cushion, the combination of declining revenue (-19.4% YoY) and massive earnings misses (most recent surprise -678.8%) points to a failing operational model. The recent price surge is disconnected from all deterministic health and value metrics.

Strengths
Strong short-term liquidity (Current Ratio: 9.22)
Significant 1-year price momentum (+223.8%)
Analyst target price ($38.75) suggests potential upside based on pipeline
Risks
Extreme valuation (P/S ratio of 106.77 is decoupled from revenue)
Negative shareholder equity (Price/Book: -1.64)
Severe operational inefficiency (Operating Margin: -2393.75%)
YDES BEARISH

YDES exhibits severe financial instability characterized by a weak Piotroski F-Score of 3/9 and a catastrophic technical trend. While the company maintains a pristine balance sheet with zero debt and an exceptional current ratio of 13.18, these are offset by an absurd Price-to-Sales ratio of 724.75 and deeply negative operating margins (-444.59%). The stock is currently in a freefall, trading near its 52-week low after a 60.7% one-year decline, suggesting a massive loss of investor confidence despite high year-over-year revenue growth.

Strengths
Zero debt (Debt/Equity: 0.00)
Exceptional short-term liquidity (Current Ratio: 13.18)
Strong year-over-year revenue growth (95.60%)
Risks
Extreme valuation disconnect (P/S ratio of 724.75)
Severe operational losses (Profit Margin: -276.58%)
Strongly bearish technical momentum (0/100 trend score)

Compare Another Pair

SRZN vs YDES: Head-to-Head Comparison

This page compares Surrozen, Inc. (SRZN) and YD Bio Ltd (YDES) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile